On June 30, HJ Science-B fell 8.07% in regular trading, trading at HK$37.3/share, with turnover of approximately HK$1.82 million.

The stock continues to face heavy selling pressure following its Hong Kong listing on June 23 at an IPO price of HK$81.8/share. The company broke sharply on its debut day, closing down 56.89%, and has since remained in persistent decline. As a Chapter 18A clinical-stage biotech, HJ Science has no products approved for commercial sale, with core candidates HJ787, HJ178, and HJ891 all still in clinical development amid intense competition in each therapeutic area. The weak Hang Seng Index environment and a market-wide rotation of capital toward AI and high-growth sectors have compounded systematic selling pressure on unprofitable biotech names, further weighing on the stock.

HJ Science was co-founded by multiple PhD-level scientists and focuses on the research and development of innovative drugs targeting oncology, autoimmune diseases, and metabolic disorders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)